News Health/Medical Semaglutide: A Breakthrough in Heart Health
0
Obesity

Published :

Semaglutide: A Breakthrough in Heart Health

A groundbreaking study has revealed that semaglutide, the active ingredient in drugs like Wegovy and Ozempic, could be the most significant medical advancement since statins. Researchers found that this weight loss injection not only helps shed pounds but also dramatically reduces the risk of heart attacks, strokes, and cardiovascular-related deaths.

Cardiovascular Benefits Beyond Weight Loss

Participants taking semaglutide experienced a remarkable 20% lower risk of heart attack, stroke, or cardiovascular death. Even those with mild obesity or minimal weight loss showed improved cardiovascular outcomes. The drug's impact extends beyond weight reduction, suggesting alternative mechanisms at play.

Study Details

The study involved 17,604 adults aged 45 and over from 41 countries. Participants, previously affected by cardiovascular events, received either a 2.5mg weekly dose of semaglutide or a placebo for an average of 40 months. Semaglutide, available as Wegovy, has been prescribed for weight loss on the NHS since 2023.

Gamechanger for Cardiovascular Health

Prof. John Deanfield, lead author of the study, emphasized that semaglutide represents a gamechanger. Its potential to transform chronic age-related diseases rivals the impact statins had in the 1990s. Millions of people in the UK could benefit from routine semaglutide prescriptions in the coming years.

  • Reactions

    0
    0
    0
    0
    0
    0

    Your email address will not be published. Required fields are marked *